Lyle Probst, President, CEO & Founder of ExcitePCR, is named to a prestigious, Sept. 18th 3-person BioWatch Panel Discussion on current and future advancements in pathogen detection systems.
Pleasanton, Calif. and WASHINGTON, D.C. (PRWEB)
September 06, 2017
Lyle Probst, ExcitePCR’s President, CEO, and founder has been invited to join a prestigious three-member BioWatch panel discussion in September about current and future advancements in pathogen detection systems hosted by the National Academies of Science, Engineering and Medicine (NAS).
The panel discussion (officially titled: “Novel Technologies to Expand Capabilities”) will be held from 3:30—4:30 p.m. (ET) on Monday, September 18, 2017 at the Fred Kavli Auditorium at the NAS headquarters at 500 Fifth Street NW in Washington, D.C. This panel is part of a two-day NAS workshop on Strategies for Effective Biological Detection Systems, and it will be led and moderated by bioinformatics expert, Tom Slezak, Distinguished Member of the Technical Staff at Lawrence Livermore National Laboratory, and Program Leader, Informatics for LLNL.
“Tom’s team at Lawrence Livermore National Laboratory is on the cutting edge of identifying virulence signatures, antibiotic resistance, evidence of genetic engineering, and biohazard detection solutions,” Probst said. “So it’s a great honor to be invited to join him and my fellow panelists as we address the current and future state of pathogen detection systems during this National Academy of Sciences workshop.”
For over 17 years, Probst has been on the forefront of government- and business-led efforts to improve the ability to quickly and accurately identify harmful biological agents, including his roles as a Biomedical Scientist/Project Manager at LLNL, as Vice President of Operations & Business Development for Microfluidic Systems, as President of PositiveID, and most recently, as CEO of ExcitePCR. In fact, it was his efforts at Microfluidic and PositiveID that led to the successful development of the M-BAND system for airborne pathogen detection under a seven-year contract with the U.S. Department of Homeland Security (DHS).
ExcitePCR is currently developing its FireflyDX™ family of portable pathogen detection systems. Last…